Systemic candidiasis and infliximab therapy;Candidiasis sistémica y tratamiento con infliximab

Gastroenterologia y Hepatologia

Volumn 27, Issue 6, 2004, Pages 365-367

  Belda, A ^a,a   Hinojosa, J ^a,b   Serra, B ^a   Garcia L ^a   Merino, C ^a   Moles J R ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

^b Servicio de Medicina Interna   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CEFTRIAXONE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; VORICONAZOLE;

ADULT; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG USE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; STEROID THERAPY;

EID: 3142775744     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13062892     Document Type: Article

References (19)

1. Van Deventer S. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
2. Targan SR, Hanauer SB, Van Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
4. Regueiro M, Valentine J, Plevys S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenossum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821-6.
5. Tan MH, Gordon M, Lebwhol O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumour necrosis factor alpha monoclonal antibody. Arch Derm 2001;137:930-3.
6. Farrell RJ, Samir AS, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3491-7.
7. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
8. CCOHTA Technology Report. Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis. CCOHTA Technology Report. Issue 24, March 2002. Disponible en: http://www.ccohta.ca/ ccohta_production/entry_e.html
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359:1541-9.
10. Keane J, Gershon S, Wise R, et al. Tuberculosis associated with infliximab, a TNF-alpha neutralizing agent. N Engl J Med 2001;345:1098-104.
11. Lispsky PE, Van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis, N Engl J Med 2000;343:1594-602.
12. Warris A, Bjorneklett P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
13. Van der Klooster JM, Bosman RS, Oudemans von Straaten HM, Van der Spoel JL, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpex simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003;29:2227-329.
14. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumour necrosis factor alpha therapy. Am J Respir Crit Care Med 2003;167:1279-82.
15. Rutgeerts P. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001;15:1515-25.
16. Brieland J, Essig D, Jackson C, et al. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun 2001;69:5046-55.
17. Nikolaus S, Raedler A, Kühbacher T, Sfikas N, Fölsch U, Schreiber S. Mechanism in failure of anti-TNF for Crohn's disease. Lancet 2000;356:1475-9.
18. Present D, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double blind study. N Engl J Med 1980;302:981-7.
19. Modigliani R. Immunosuppresors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis 2000;6:251-7.